menu
    • menu
    [{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dorzolamide Hydrochloride","moa":"Carbonic anhydrase II","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Poen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Difluprednate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Laboratorios Poen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Poen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Poen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ARGENTINA","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Poen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Laboratorios Poen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Poen \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Laboratorios Poen

    Menu

    Laboratorios Poen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

                            Details : Dorzolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 12, 2023

                            Lead Product(s) : Dorzolamide Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bepotastine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment

                            Details : Bepotastine Besilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Conjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2021

                            Lead Product(s) : Bepotastine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difluprednate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Sur...

                            Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 17, 2020

                            Lead Product(s) : Difluprednate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed

                            Laboratorios Poen

                            Argentina arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost

                            Details : Latanoprost is a HPAPI drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Glaucoma, Open-Angle.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            November 06, 2017

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth